Format

Send to

Choose Destination
Br J Haematol. 2019 May;185(4):713-717. doi: 10.1111/bjh.15816. Epub 2019 Feb 21.

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).

Author information

1
Division of Haematology, Department of Haematology and Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
2
Haematology, ASST Spedali Civili di Brescia, Brescia, Italy.
3
Division of Haematology, A.U.O. Policlinico-Vittorio Emanuele-Ferrarotto, Catania, Italy.
4
Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
5
Haematology, S.C.D.U. Ematologia Universitaria, Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy.
6
Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
7
SC Ematologia, Azienda Ospedaliera Città della Salute e della Scienza, Torino, Italy.
8
AUSL-IRCCS Reggio Emilia, Hematology, Italy.
9
Ematologia, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy.

Abstract

Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.

KEYWORDS:

composite lymphoma ; autologous stem cell transplantation; follicular lymphoma; histological transformation; rituximab maintenance

PMID:
30793297
DOI:
10.1111/bjh.15816

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center